EP1605931A4 - Drug formulations having long and medium chain triglycerides - Google Patents

Drug formulations having long and medium chain triglycerides

Info

Publication number
EP1605931A4
EP1605931A4 EP03816401A EP03816401A EP1605931A4 EP 1605931 A4 EP1605931 A4 EP 1605931A4 EP 03816401 A EP03816401 A EP 03816401A EP 03816401 A EP03816401 A EP 03816401A EP 1605931 A4 EP1605931 A4 EP 1605931A4
Authority
EP
European Patent Office
Prior art keywords
long
medium chain
chain triglycerides
drug formulations
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03816401A
Other languages
German (de)
French (fr)
Other versions
EP1605931A1 (en
Inventor
Edgar H Ulm
Robert Mansfield
Marcus Boehm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conforma Therapeutics Corp
Original Assignee
Conforma Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/010533 external-priority patent/WO2003086381A1/en
Application filed by Conforma Therapeutics Corp filed Critical Conforma Therapeutics Corp
Publication of EP1605931A1 publication Critical patent/EP1605931A1/en
Publication of EP1605931A4 publication Critical patent/EP1605931A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03816401A 2003-03-13 2003-10-04 Drug formulations having long and medium chain triglycerides Withdrawn EP1605931A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US45481203P 2003-03-13 2003-03-13
US454812P 2003-03-13
PCT/US2003/010533 WO2003086381A1 (en) 2002-04-10 2003-04-04 Ansamycin formulations and methods for producing and using same
WOPCT/US03/10533 2003-04-04
US47843003P 2003-06-12 2003-06-12
US478430P 2003-06-12
US49105003P 2003-07-29 2003-07-29
US491050P 2003-07-29
PCT/US2003/031667 WO2004082676A1 (en) 2003-03-13 2003-10-04 Drug formulations having long and medium chain triglycerides

Publications (2)

Publication Number Publication Date
EP1605931A1 EP1605931A1 (en) 2005-12-21
EP1605931A4 true EP1605931A4 (en) 2009-04-29

Family

ID=35351739

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03816401A Withdrawn EP1605931A4 (en) 2003-03-13 2003-10-04 Drug formulations having long and medium chain triglycerides

Country Status (6)

Country Link
EP (1) EP1605931A4 (en)
JP (1) JP2006514994A (en)
CN (1) CN101756961A (en)
AU (1) AU2003277299B2 (en)
CA (1) CA2518836A1 (en)
WO (1) WO2004082676A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4869077B2 (en) 2003-12-23 2012-02-01 インフィニティー ディスカヴァリー インコーポレイテッド Analogs of benzoquinone-containing ansamycins for cancer treatment
EP1817295B1 (en) 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2596867A1 (en) * 2005-02-28 2006-09-08 Kosan Biosciences Incorporated Pharmaceutical formulations containing 17-allylamino-17-demethoxygeldanamycin
CA2603462A1 (en) * 2005-04-07 2006-10-09 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same
EP1874296A4 (en) 2005-04-29 2010-06-30 Kosan Biosciences Inc Method of treating multiple myeloma using 17-aag of 17-ag of a prodrug of either
AU2006338265B2 (en) 2005-08-18 2011-04-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
CN101360492A (en) * 2005-12-01 2009-02-04 康福玛医药公司 Compositions containing ansamycin
PE20081506A1 (en) 2006-12-12 2008-12-09 Infinity Discovery Inc ANSAMYCIN FORMULATIONS
WO2010045442A1 (en) 2008-10-15 2010-04-22 Infinity Discovery, Inc. Ansamycin hydroquinone compositions
KR101834577B1 (en) * 2009-08-14 2018-03-05 옵코 헬스, 인크. Intravenous formulations of neurokinin-1 antagonists
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
JP2014534228A (en) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション Combination therapy of platinum-containing agents and HSP90 inhibitors
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CN106018611B (en) * 2016-06-21 2018-08-24 广州白云山汉方现代药业有限公司 A kind of assay method of gas chromatogram fixative detection medium chain triglyceride content

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003086381A1 (en) * 2002-04-10 2003-10-23 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001342A1 (en) * 1993-06-29 1995-01-12 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
DE10036871A1 (en) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersions for the formulation of poorly or poorly soluble active ingredients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003086381A1 (en) * 2002-04-10 2003-10-23 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same

Also Published As

Publication number Publication date
EP1605931A1 (en) 2005-12-21
WO2004082676A1 (en) 2004-09-30
CN101756961A (en) 2010-06-30
AU2003277299A1 (en) 2004-10-11
AU2003277299B2 (en) 2009-12-10
CA2518836A1 (en) 2004-09-30
JP2006514994A (en) 2006-05-18

Similar Documents

Publication Publication Date Title
IL170758A0 (en) 7-amino-isoindolyl compounds and their pharmaceutical uses
HK1084883A1 (en) 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
IL172824A0 (en) Pharmaceutical formulations
GB0302671D0 (en) Pharmaceutical formulations
IL170313A (en) Diarylcycloalkyl derivatives and pharmaceutical compositions comprising them
EP1819746A4 (en) Tmxdi-based oligomer and formulations containing it
HK1088837A1 (en) Clk-peptide and slk-peptide
EP1605931A4 (en) Drug formulations having long and medium chain triglycerides
IL172087A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
PL1655026T3 (en) Solid pharmaceutical formulations comprising diacereine and meloxicam
EP1689629A4 (en) Wheelchair designs and related enhancements
GB0302672D0 (en) Pharmaceutical formulations
GB0316341D0 (en) Pharmaceutical formulations
GB0317877D0 (en) Pharmaceutical combinations and formulations with improved stability
GB0316910D0 (en) Fluorocombretastatin and derivatives thereof
GB0318546D0 (en) Quinoxalinones and their use
GB0300804D0 (en) Compounds and their use
GB0301143D0 (en) Compounds and their use
GB0307231D0 (en) 7-Nitroindoline derivatives and their uses
GB0324912D0 (en) Pharmaceutical formulations
GB0316338D0 (en) Pharmaceutical formulations
GB0326642D0 (en) Pharmaceutical formulations
GB0316343D0 (en) Pharmaceutical formulations
GB0327722D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051004

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: BOEHM, MARCUS

Inventor name: MANSFIELD, ROBERT

Inventor name: ULM, EDGAR, H.

A4 Supplementary search report drawn up and despatched

Effective date: 20090401

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20090326BHEP

Ipc: A61K 47/14 20060101ALI20090326BHEP

Ipc: A61K 9/19 20060101ALI20090326BHEP

Ipc: A61K 9/107 20060101ALI20090326BHEP

Ipc: A61K 31/395 20060101ALI20090326BHEP

Ipc: A61K 31/00 20060101ALI20090326BHEP

Ipc: A61K 31/33 20060101AFI20041006BHEP

17Q First examination report despatched

Effective date: 20090708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100921